Ivabradine
FDA-approved product (solution, oral), marketed as Corlanor, Ivabradine Hydrochloride.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Angina pectoris
- Cardiovascular disease
- Congestive heart failure
- Heart failure
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other cardiac preparations
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA49.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli45.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae33.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis38.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Ivabradine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Preoperative Ivabradine Doses for Hemodynamic Stability in FESS
NCT07797946 · start 2026-08-01
Registered record
- Registry ID
- NCT07797946
- Conditions
- Hemodynamic Instability
- Interventions
- Ivabradine 5 mg/5 mg regimen; Ivabradine 5 mg/7.5 mg regimen; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Not yet recruiting
- Start
- 2026-08-01
- Completion
- 2027-02-01
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHemodynamic InstabilityInterventionIvabradine 5 mg/5 mg regimen; Ivabradine 5 mg/7.5 mg regimen; PlaceboPhaseNot applicableRegistry statusNot yet recruitingRECOVER-AUTONOMIC Platform Protocol
NCT06305780 · start 2024-03-11
Registered record
- Registry ID
- NCT06305780
- Conditions
- Long COVID; Long Covid19; Long Covid-19
- Interventions
- IVIG + Coordinated Care; IVIG Placebo + Coordinated Care; Ivabradine + Coordinated Care; Ivabradine Placebo + Coordinated Care; IVIG + Usual Care; IVIG Placebo + Usual Care; Ivabradine + Usual Care; Ivabradine Placebo + Usual Care
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2024-03-11
- Completion
- 2025-07-09
- Enrolment
- 381
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLong COVID; Long Covid19; Long Covid-19InterventionIVIG + Coordinated Care; IVIG Placebo + Coordinated Care; Ivabradine + Coordinated Care; Ivabradine Placebo + Coordinated Care +4 morePhasePhase 2Registry statusCompletedRECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)
NCT06305806 · start 2024-03-11
Registered record
- Registry ID
- NCT06305806
- Conditions
- Long COVID; Long Covid19; Long Covid-19
- Interventions
- Ivabradine; Ivabradine Placebo; Coordinated Care; Usual Care
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2024-03-11
- Completion
- 2025-12-17
- Enrolment
- 181
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLong COVID; Long Covid19; Long Covid-19InterventionIvabradine; Ivabradine Placebo; Coordinated Care; Usual CarePhasePhase 2Registry statusCompletedIvabradine for Long-Term Effects of COVID-19 With POTS Cohort
NCT05481177 · start 2023-06-14
Registered record
- Registry ID
- NCT05481177
- Conditions
- Long Haul COVID; Postural Orthostatic Tachycardia Syndrome
- Interventions
- Ivabradine
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2023-06-14
- Completion
- 2024-09-01
- Enrolment
- 250
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLong Haul COVID; Postural Orthostatic Tachycardia SyndromeInterventionIvabradinePhasePhase 4Registry statusUnknownEffect of Heart Rate Control With Ivabradine on Hemodynamic in Patients With Sepsis
NCT05882708 · start 2023-06-01
Registered record
- Registry ID
- NCT05882708
- Conditions
- Sepsis; Ivabradine; Hemodynamics; Heart Rate Control
- Interventions
- Ivabradine
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Recruiting
- Start
- 2023-06-01
- Completion
- 2027-05-31
- Enrolment
- 172
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSepsis; Ivabradine; Hemodynamics; Heart Rate ControlInterventionIvabradinePhasePhase 4Registry statusRecruitingRole of Ivabradine on Heart Rate and Quality of Life in Patients With Mitral Stenosis in Sinus Rhythm
NCT06371222 · start 2023-02-01
Registered record
- Registry ID
- NCT06371222
- Conditions
- Mitral Stenosis
- Interventions
- Ivabradine; Beta blocker
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2023-02-01
- Completion
- 2024-02-01
- Enrolment
- 42
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMitral StenosisInterventionIvabradine; Beta blockerPhasePhase 4Registry statusCompletedEmpower the Heart of Patients With Terminal Cancer Using Cardiac Medicines Trial
NCT05636774 · start 2022-12-12
Registered record
- Registry ID
- NCT05636774
- Conditions
- Patients With Advanced Cancer Receiving Specialized Palliative Care
- Interventions
- Heart failure medication; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2022-12-12
- Completion
- 2025-03-01
- Enrolment
- 97
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPatients With Advanced Cancer Receiving Specialized Palliative CareInterventionHeart failure medication; PlaceboPhaseNot applicableRegistry statusCompletedthe Role of Ivabradine in Causing AF in Patients With Chronic Coronary Syndrome
NCT05168189 · start 2022-08
Registered record
- Registry ID
- NCT05168189
- Conditions
- AF - Atrial Fibrillation
- Interventions
- Ivabradine; transthoracic echo; 24 hours holter
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Unknown
- Start
- 2022-08
- Completion
- 2024-01
- Enrolment
- 180
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAF - Atrial FibrillationInterventionIvabradine; transthoracic echo; 24 hours holterPhaseNot recordedRegistry statusUnknownIvabradine Effects in Cardiogenic Shock Requiring Inotropic Support
NCT05594342 · start 2022-07-01
Registered record
- Registry ID
- NCT05594342
- Conditions
- Heart Failure; Cardiogenic Shock; Ischemic Heart Disease
- Interventions
- Ivabradine 7.5Mg Tab; DOBUTamine Injectable Solution
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 2022-07-01
- Completion
- 2023-01-01
- Enrolment
- 200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHeart Failure; Cardiogenic Shock; Ischemic Heart DiseaseInterventionIvabradine 7.5Mg Tab; DOBUTamine Injectable SolutionPhasePhase 3Registry statusUnknownIvabradine for Prevention of Myocardial Injury After Noncardiac Surgery Trial (PREVENT-MINS)
NCT05279651 · start 2022-06-13
Registered record
- Registry ID
- NCT05279651
- Conditions
- Myocardial Injury After Noncardiac Surgery (MINS); Myocardial Ischemia
- Interventions
- Ivabradine; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Active not recruiting
- Start
- 2022-06-13
- Completion
- 2026-06-30
- Enrolment
- 2,146
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMyocardial Injury After Noncardiac Surgery (MINS); Myocardial IschemiaInterventionIvabradine; PlaceboPhasePhase 3Registry statusActive not recruitingClinical Study of CMR to Evaluate the Effect of Ivabradine on the Improvement of Left Ventricular Remodeling in STEMI Patients After Primary PCI
NCT05348057 · start 2021-08-01
Registered record
- Registry ID
- NCT05348057
- Conditions
- Cardiovascular Diseases
- Interventions
- Ivabradine
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2021-08-01
- Completion
- 2022-09-01
- Enrolment
- 240
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCardiovascular DiseasesInterventionIvabradinePhasePhase 4Registry statusUnknownCompression Garments in the Community With POTS
NCT04881318 · start 2021-05-17
Registered record
- Registry ID
- NCT04881318
- Conditions
- Postural Orthostatic Tachycardia Syndrome
- Interventions
- Waist-High Compression Tights; Abdominal Compression Garments; Medications that modulate heart rate and blood pressure
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Recruiting
- Start
- 2021-05-17
- Completion
- 2026-12-31
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostural Orthostatic Tachycardia SyndromeInterventionWaist-High Compression Tights; Abdominal Compression Garments; Medications that modulate heart rate and blood pressurePhaseNot applicableRegistry statusRecruitingEffect of Ivabradine on Levcromakalim-Induced Symptoms in Individuals With Migraine Without Aura (ILIM)
NCT04853797 · start 2021-05-11
Registered record
- Registry ID
- NCT04853797
- Conditions
- Headache; Migraine Without Aura
- Interventions
- Levcromakalim; Ivabradine; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2021-05-11
- Completion
- 2025-07-06
- Enrolment
- 37
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHeadache; Migraine Without AuraInterventionLevcromakalim; Ivabradine; PlaceboPhaseNot applicableRegistry statusCompletedIvabradine for Heart Rate Control In Septic Shock
NCT04031573 · start 2021-02-26
Registered record
- Registry ID
- NCT04031573
- Conditions
- Septic Shock
- Interventions
- Ivabradine; Ivabradine; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2021-02-26
- Completion
- 2026-04-14
- Enrolment
- 429
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSeptic ShockInterventionIvabradine; Ivabradine; PlaceboPhasePhase 3Registry statusCompletedCrossover Study of Propranolol vs Ivabradine in POTS
NCT04186286 · start 2021-02-01
Registered record
- Registry ID
- NCT04186286
- Conditions
- Postural Tachycardia Syndrome
- Interventions
- Ivabradine 4-week course; Propranolol 4-week course; Placebo 4-week course
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2021-02-01
- Completion
- 2026-12-31
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostural Tachycardia SyndromeInterventionIvabradine 4-week course; Propranolol 4-week course; Placebo 4-week coursePhasePhase 2Registry statusRecruiting